Glucagon‐like peptide‐1 therapy in people with obesity restores natural killer cell metabolism and effector function
Authors:
Open Access
Abstract
Objective: People with obesity (PWO) have functionally defective natural killer (NK) cells, with a decreased capacity to produce cytokines and kill target cells, underpinned by defective cellular metabolism. It is plausible that the changes in peripheral NK cell activity are contributing to the multimorbidity in PWO, which includes an increased risk of cancer. This study investigated whether therapy with long‐acting glucagon‐like peptide‐1 (GLP‐1) analogues, which are an effective treatment for obesity, could restore NK cell functionality in PWO.Methods: In a cohort of 20 PWO, this study investigated whether 6 months of once weekly GLP‐1 therapy (semaglutide) could restore human NK cell function and metabolism using multicolor flow cytometry, enzyme‐linked immunosorbent assays, and cytotoxicity assays.Results: These data demonstrate that PWO who received GLP‐1 therapy have improved NK cell function, as measured by cytotoxicity and interferon‐γ/granzyme B production. In addition, the study demonstrates increases in a CD98‐mTOR‐glycolysis metabolic axis, which is critical for NK cell cytokine production. Finally, it shows that the reported improvements in NK cell function appear to be independent of weight loss.Conclusions: The restoration, by GLP‐1 therapy, of NK cell functionality in PWO may be contributing to the overall benefits being seen with this class of medication.Keywords
Funding Information
- Health Research Board (ILP‐POR‐2019‐110)
This publication has 46 references indexed in Scilit:
- Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiationNature Immunology, 2013
- Obesity is associated with impaired immune response to influenza vaccination in humansInternational Journal of Obesity, 2011
- Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasisDiabetologia, 2011
- The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cellsBreast Cancer Research and Treatment, 2011
- B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodiesNature Medicine, 2011
- Natural Killer Cells in Obesity: Impaired Function and Increased Susceptibility to the Effects of Cigarette SmokePLOS ONE, 2010
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent PathwaysCirculation, 2008
- NK cell regulation of T cell-mediated responsesMolecular Immunology, 2005
- Natural killer cells, viruses and cancerNature Reviews Immunology, 2001
- Deficiency of active natural killer cells in the Chediak-Higashi syndrome. Localization of the defect using a single cell cytotoxicity assay.Journal of Clinical Investigation, 1982